Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Preferred Stock Liabilities (2023 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Preferred Stock Liabilities over the past 3 years, most recently at $46.1 million for Q2 2025.

  • For Q2 2025, Preferred Stock Liabilities rose 8.24% year-over-year to $46.1 million; the TTM value through May 2025 reached $46.1 million, up 8.24%, while the annual FY2025 figure was $46.1 million, 8.24% up from the prior year.
  • Preferred Stock Liabilities for Q2 2025 was $46.1 million at Lifecore Biomedical, Inc. \De\, up from $45.2 million in the prior quarter.
  • Over five years, Preferred Stock Liabilities peaked at $46.1 million in Q2 2025 and troughed at $38.5 million in Q1 2023.
  • A 3-year average of $42.2 million and a median of $42.2 million in 2024 define the central range for Preferred Stock Liabilities.
  • Biggest five-year swings in Preferred Stock Liabilities: grew 8.34% in 2024 and later rose 8.24% in 2025.
  • Year by year, Preferred Stock Liabilities stood at $40.9 million in 2023, then grew by 8.28% to $44.3 million in 2024, then increased by 4.03% to $46.1 million in 2025.
  • Business Quant data shows Preferred Stock Liabilities for LFCR at $46.1 million in Q2 2025, $45.2 million in Q1 2025, and $44.3 million in Q4 2024.